Use of mesenchymal stem cells in therapy of tuberculosis
https://doi.org/10.21292/2075-1230-2022-100-4-62-66
Abstract
This review presents data from 29 publications on the use of mesenchymal stem cells in the therapy of tuberculosis of various localizations. It also describes some mechanisms of interaction between mesenchymal stem cells and M. tuberculosis.
About the Authors
А. N. Remezova
St. Petersburg University
Russian Federation
Russian Federation
Anna N. Remezova, Resident Physician of Hospital Surgery Department
7-9, Universitetskaya Nab., St. Petersburg, 199034
А. А. Gorelova
St. Petersburg Research Institute of Phthisiopulmonology; St. Petersburg University
Russian Federation
Russian Federation
Anna A. Gorelova, Assistant
2-4, Ligovsky Ave., St. Petersburg, 191036
7-9, Universitetskaya Nab., St. Petersburg, 199034
T. I. Vinogradova
St. Petersburg Research Institute of Phthisiopulmonology
Russian Federation
Russian Federation
Tatyana I. Vinogradova, Doctor of Medical Sciences, Professor, Senior Researcher
2-4, Ligovsky Ave., St. Petersburg, 191036
А. I. Gorelov
St. Petersburg University; Pokrovskaya City Hospital
Russian Federation
Russian Federation
Andrey I. Gorelov, Doctor of Medical Sciences, Professor, Professor of Urology Department, Medicine Faculty
7-9, Universitetskaya Nab., St. Petersburg, 199034
А. I. Gorbunov
St. Petersburg Research Institute of Phthisiopulmonology
Russian Federation
Russian Federation
Aleksandr I. Gorbunov, Researcher in Urology, Gynecology and Abdominal Surgery
2-4, Ligovsky Ave., St. Petersburg, 191036
N. M. Yudintseva
Institute of Cytology, the Russian Academy of Sciences
Russian Federation
Russian Federation
Natalia M. Yudintseva, Candidate of Biological Sciences, Senior Researcher
4, Tikhoretskiy Ave., St. Petersburg 194064
References
1. Аriel B.M., Guseynova F.M., Vinogradova T.I. et al. Mesenchymal stem cells of the bone marrow in treatment of genital tuberculosis in rabbits (experimental research with morphological control). Obzory Po Klinicheskoy Farmakologii I Lekarstvennoy Terapii, 2017, vol. 15, no. 2, pp. 47-55. (In Russ.)
2. Guseynova F.M., Vinogradova T.I., Zabolotnykh N.V. at al. The impact of cellular therapy with mesenchymal stem cells of bone marrow on reparation at experimental tuberculous salpingitis. Meditsinsky Alyans, 2017, no. 3, pp. 35-43. (In Russ.)
3. Erokhin V.V., Vasilyeva I.А., Konoplyannikov А.G. et al. System transplantation of self-specific mesenchymal bone marrow stem cells for treatment of multiple drug resistant pulmonary tuberculosis patients. Tuberculosis and Lung Diseases, 2008, vol. 85, no. 10, pp. 3-6. (In Russ.)
4. Orlova N.V., Muraviev А.N., Blyum N.M. at al. Experimental urinary bladder reconstruction in the rabbit using self-specific cells of various tissue origin. Meditsinsky Alyans, 2016, no. 1, pp. 50-52. (In Russ.)
5. Cohen K.A., Abeel T., McGuire A.M. et al. Evolution of extensively drug-resistant tuberculosis over four decades revealed by whole genome sequencing of Mycobacterium tuberculosis from KwaZulu-Natal, South Africa. Intern. J. Mycobacter., 2015, vol. 4, pp. 24-25. doi:10.1016/j.ijmyco.2014.11.028.
6. Danjuma L., Mok P.L., Higuchi A. et al. Modulatory and regenerative potential of transplanted bone marrow-derived mesenchymal stem cells on rifampicin-induced kidney toxicity. Regenera. Ther., 2018, vol. 9, pp. 100-110. doi:10.1016/j.reth.2018.09.001.
7. Das B., Kashino S.S., Pulu I. et al. CD271+ bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis. Sci. Translat. Med., 2013, vol. 5, iss. 170, pp. 170. doi: 10.1126/scitranslmed.3004912.
8. Espinal M.A., Laszlo A., Simonsen L. et al. Global trends in resistance to antituberculosis drugs. New Engl. J. Med., 2001, vol. 344, iss. 17, pp. 1294-1303. doi: 10.1056/NEJM200104263441706.
9. Fatima S., Kamble,S.S., Dwivedi V.P. et al. Mycobacterium tuberculosis programs mesenchymal stem cells to establish dormancy and persistence. J. Clin. Invest., 2020, vol. 130, iss. 2, pp. 655-661. doi: 10.1172/JCI128043.
10. Gomez J.E., McKinney J.D. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis, 2004, vol. 84, iss. 1-2. pp. 29-44. doi:10.1016/j.tube.2003.08.003.
11. Gutierrez M.G., Master S.S., Singh S.B. et al. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell, 2004, vol. 119, iss. 6, pp. 753-766. doi:10.1016/j.cell.2004.11.038.
12. Islam M.N., Das S.R., Emin M.T. et al. Mitochondrial transfer from bone-marrow–derived stromal cells to pulmonary alveoli protects against acute lung injury. Nature Med., 2012, vol. 18, iss. 5, pp. 759-765. doi:10.1038/nm.2736.
13. Khan A., Mann L., Papanna R. et al. Mesenchymal stem cells internalize Mycobacterium tuberculosis through scavenger receptors and restrict bacterial growth through autophagy. Sci. Reports, 2017, vol. 7, iss. 1, pp. 1-15. doi:10.1038/s41598-017-15290-z.
14. Levitte S., Adams K.N., Berg R.D. et al. Mycobacterial acid tolerance enables phagolysosomal survival and establishment of tuberculous infection in vivo. Cell Host & Microbe, 2016, vol. 20, iss. 2, pp. 250-258. doi:10.1016/j.chom.2016.07.007.
15. Matthay M.A., Goolaerts A., Howard J.P. et al. Mesenchymal Stem Cells for Acute Lung Injury: Preclinical Evidence. Crit. Care Med., 2010, vol. 38, iss. 10, pp. 569-573. doi: 10.1097/CCM.0b013e3181f1ff1d.
16. Mei S.H., McCarter S.D., Deng Y. et al. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med., 2007, vol. 4, iss. 9, pp. e269. doi:10.1371/journal.pmed.0040269.
17. Parida S.K. Madansein R., Singh N. et al. Cellular therapy in tuberculosis. Intern. J. Infect. Dis., 2015, vol. 32, pp. 32-38. doi:10.1016/j.ijid.2015.01.016.
18. Raghuvanshi S., Sharma P., Singh S. et al. Mycobacterium tuberculosis evades host immunity by recruiting mesenchymal stem cells. Proceedings of the National Academy of Sciences, 2010, vol. 107, iss. 50, pp. 21653-21658. doi:10.1073/pnas.1007967107.
19. Shah N.S., Wright A., Bai G.H. et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg. Infect. Dis., 2007, vol. 13, iss. 3, pp. 380. doi:10.3201/eid1303.061400.
20. Sinclair K., Yerkovich S.T., Chambers D.C. Mesenchymal stem cells and the lung. Respirology, 2013, vol. 18, iss. 3, pp. 397-411. doi:10.1111/resp.12050.
21. Skrahin A., Ahmed R.K., Ferrara G. et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir. Med., 2014, vol. 2, iss. 2, pp. 108-122. doi:10.1016/S2213-2600(13)70234-0.
22. Spees J.L., Olson S.D., Whitney M.J. et al. Mitochondrial transfer between cells can rescue aerobic respiration. Proceedings of the National Academy of Sciences, 2006, vol. 103, iss. 5, pp. 1283-1288. doi:10.1073/pnas.0510511103.
23. Sturgill-Koszycki S., Schlesinger P.H., Chakraborty P. et al. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science, 1994, vol. 263, iss. 5147, pp. 678-681. doi:10.1126/science.8303277.
24. Tardif S., Ross C., Bergman P. et al. Testing efficacy of administration of the antiaging drug rapamycin in a nonhuman primate, the common marmoset. J. Gerontology Series A: Biomed. Sci. Med. Sci., 2015, vol. 70, iss. 5, pp. 577-588. doi:10.1093/gerona/glu101.
25. Tropea K.A., Leder E., Aslam M. et al. Bronchioalveolar stem cells increase after mesenchymal stromal cell treatment in a mouse model of bronchopulmonary dysplasia. Amer. J. Physiology-Lung Cell Molec. Physiol., 2012, vol. 302, iss. 9, pp. 829-837. doi:10.1152/ajplung.00347.2011.
26. van der Wel N., Hava D., Houben D. et al. M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell, 2007, vol. 129, iss. 7, pp. 1287-1298. doi:10.1016/j.cell.2007.05.059.
27. Velayati A.A. et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest, 2009, vol. 136, iss. 2, pp. 420-425. doi:10.1378/chest.08-2427.
28. Wakamoto Y., Dhar N., Chait R. et al. Dynamic persistence of antibiotic-stressed mycobacteria. Science, 2013, vol. 339, iss. 6115, pp. 91-95. doi: 10.1126/science.1229858.
29. Yudintceva N.M., Bogolyubova I.O., Muraviov A.N. et al. Application of the allogenic mesenchymal stem cells in the therapy of the bladder tuberculosis. J. Tissue Eng. Regener. Med., 2018, vol. 12, iss. 3, pp. 1580-1593. doi:10.1002/term.2583.
Review
For citations:
Remezova А.N., Gorelova А.А., Vinogradova T.I., Gorelov А.I., Gorbunov А.I., Yudintseva N.M. Use of mesenchymal stem cells in therapy of tuberculosis. Tuberculosis and Lung Diseases. 2022;100(4):62-66. (In Russ.) https://doi.org/10.21292/2075-1230-2022-100-4-62-66
Views:
562
Email this article 